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S U M M A R Y
Objectives: To give an overview of the HIV epidemic in the Middle East and North Africa (MENA) region.
Methods: Articles on the MENA region were reviewed.
Results: The MENA region comprises a geographically deﬁned group of countries including both high-
income, well-developed nations and low- and middle-income countries. While the annual number of
new HIV infections in Sub-Saharan Africa has declined by 33% since 2005, new HIV infections in the
MENA region have increased by 31% since 2001, which is the highest increase among all regions in the
world. Moreover, the number of AIDS-related deaths in 2013 was estimated to be 15 000, representing a
66% increase since 2005. However, the current prevalence of 0.1% is still among the lowest rates globally.
There is substantial heterogeneity in HIV epidemic dynamics across MENA, and different risk contexts
are present throughout the region. Despite unfavorable conditions, many countries in the region have
put signiﬁcant effort into scaling up their response to this growing epidemic, while in others the
response to HIV is proving slower due to denial, stigma, and reluctance to address sensitive issues.
Conclusions: The HIV epidemic in the MENA region is still at a controllable level, and this opportunity
should not be missed.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. An overview of the epidemic
The Middle East and North Africa (MENA) region comprises a
geographically deﬁned group of countries including both high-
income, well-developed nations and low- and middle-income
countries. It has become the center of attention during the past
few years due to recent social and political movements commonly
referred to as the Arab Spring.1,2 An important characteristic of the* Corresponding author at: Dana-Farber Cancer Institute, Dept of Cancer
Immunology and Virology, Harvard Medical School, Dept of Global Health and
Social Medicine, 450 Brookline Ave, CLSB-1010 Boston, MA 02215.
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).region is its steadily increasing population of young adults, who
comprise 10% of the world’s population in the 15–49 years age
group.3 These demographic, social, and political trends are impor-
tant factors affecting many public health issues facing the region.
This article reviews recent trends in HIV/AIDS epidemiology in
this large and diverse region. The following 24 countries or territories
are considered: Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran,
Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan,
Palestine, Qatar, Saudi Arabia, Somalia, Sudan, South Sudan, Syria,
Tunisia, United Arab Emirates (UAE), and Yemen; all of these are
included in the MENA deﬁnitions of the Joint United Nations Program
on HIV/AIDS (UNAIDS) and the Eastern Mediterranean Regional
Ofﬁce of the World Health Organization (WHO/EMRO).4,5
From 2001 to 2013, the annual number of new HIV infections
declined by 38% globally, followed by a signiﬁcant decline in AIDS-
related deaths.6 However, trends in new infections have differed
among regions, among countries within one region, and among key
populations (KPs) in and across regions and countries. While the
annual number of new HIV infections in Sub-Saharan Africa hasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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in Eastern Europe, MENA, and Central Asia in recent years. The rising
trends in new infections are a cause for serious concern in MENA.
Since 2001, newly identiﬁed HIV infections in this region have
increased by 31%, from 19 000 to 25 000, which is the highest
increase among all regions in the world.6While some of this increase
can be attributed to increased testing and awareness, there is no
doubt that a considerable number of cases are new transmissions.
Moreover, the number of AIDS-related deaths in 2013 was estimated
to be 15 000, representing a 66% increase since 2005.6
Accurate understanding of the epidemiological features of the
HIV epidemic in the MENA region has been slow due to difﬁculties
inherent to a relatively low HIV prevalence in the total population, in
addition to late and insufﬁcient investment in surveillance systems
and collection and analysis of data pertinent to the epidemic
situation. Moreover, many studies conducted in the region have
remained unpublished in the scientiﬁc literature; such studies are
only available in the form of reports or articles in non-indexed
journals that are difﬁcult to access. This means that data have not
been analyzed or synthesized at the country or regional level, and no
critical assessment of the quality of available evidence has been
conducted. However, more peer-reviewed publications related to
the HIV epidemic in the region are being published,3 and substantial
efforts have been made to characterize the epidemic in recent years.7
There is substantial heterogeneity in HIV epidemic dynamics
across MENA, and different risk contexts are present throughout
the region. Although the number of people living with HIV (PLWH)
in the MENA region has increased signiﬁcantly over the last
decade, the current prevalence of 0.1% is still among the lowest
rates globally. Five countries – Algeria, Islamic Republic of Iran,
Morocco, Somalia, and Sudan – account for 88% of these PLWH.6
In 2013, the Islamic Republic of Iran accounted for 30% of all
HIV-positive people in the region, with an estimated number of
70 000 (47 000–110 000) PLWH. In Sudan, 49 000 (34 000–70 000)
people were living with HIV, representing 21% of the regional
estimate.6 Similarly, Iran ranked ﬁrst among other countries
regarding new HIV infections and AIDS-related deaths, followed by
Sudan, Somalia, and Morocco.6
Overall, the major route of infection in the MENA region seems
to be sexual transmission. In 2011, heterosexual sex was the most
common reported mode of HIV transmission among men in Tunisia
(44.4%), UAE (50.0%), Syria (54.5%), Jordan (66.7%), Morocco
(81.9%), Kuwait (100%), and Palestine (100%).8 However, a range
of challenges including (but not limited to) those listed below, limit
interventions to determine the actual sexual trends, making the
current data unreliable.
 The prevalence data available for KPs are principally derived
from passive surveillance data, which tend to underestimate the
role of high-risk behaviors because of individuals’ fear of
disclosure.9
 There is intense HIV-related stigma and discrimination in the
region, which is likely a major challenge for behavioral
research.10
 Same-sex conduct is illegal in 76 countries, 19 of which are in
MENA. In seven countries, including Iran, Saudi Arabia, Somalia,
Sudan, and Yemen, homosexual acts are subject to the death
penalty in some cases.6 Other countries, including Algeria, Egypt,
Iraq, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, the Syrian
Arab Republic, Tunisia, and the UAE, either criminalize adult
consensual same-sex sexual conduct or have criminally prose-
cuted lesbian, gay, bisexual, and transgender people under other
laws on the basis of their sexual orientation and gender identity.6
 Cultural and religious norms disapproving and penalizing sex
between men may contribute to the nondisclosure of homosex-
ual orientation and/or sexual conduct.11Other challenges that may be related to HIV surveillance in the
MENA countries include infrequent surveillance of populations
most at risk of HIV infection, lack of behavioral data, over-reliance
on HIV case reporting and facility-based surveillance, and limited
quality of HIV surveillance in general.12
For the year 2011, 14 countries provided data on reported HIV
cases for the WHO (Afghanistan, Iran, Jordan, Kuwait, Lebanon,
Morocco, Oman, Palestine, Saudi Arabia, Sudan, South Sudan, Syria,
Tunisia, and UAE).8 In the UNAIDS Gap Report (2014), data
regarding the MENA region were available from only 10 countries:
Afghanistan, Algeria, Djibouti, Egypt, Iran, Morocco, Somalia,
Sudan, Tunisia, and Yemen; the report did not include estimates
from the remaining countries (Bahrain, Iraq, Jordan, Kuwait,
Lebanon, Libya, Oman, Palestine, Qatar, Saudi Arabia, South Sudan,
Syria, and UAE).6
Only three countries – South Sudan, Djibouti, and Somalia – in
the MENA region have generalized epidemics; the remaining
countries have an estimated HIV prevalence in the general
population below 1%, with either low-level epidemics or HIV
epidemics concentrated in populations most at risk of HIV, and
limited spread to the general population.13 The HIV burden seems
to be mainly concentrated among people who inject drugs (PWID),
migrants, sex workers, and men who have sex with men (MSM).6
While only four countries – Djibouti, Iran, Morocco, and
Pakistan – can be classiﬁed as having fully functioning HIV
surveillance systems, HIV prevalence data for KPs most at risk of
HIV infection are still not available for Bahrain, Iraq, Kuwait, Libya,
Oman, Qatar, Saudi Arabia, South Sudan, Syria and UAE. On the
other hand, HIV prevalence estimates from more than three rounds
of bio-behavioral surveys (BBS) are available in Pakistan. In
addition, Egypt, Lebanon, and Tunisia have conducted integrated
bio-behavioral surveys (IBBS) in all three key transmission groups:
female sex workers (FSWs), PWID, and MSM.13
2. Key populations
2.1. People who inject drugs
Injected drug use is a persistent and growing problem in MENA.
According to the United Nations Ofﬁce on Drugs and Crime, 83% of
the global supply of heroin is produced in Afghanistan, and >75% of
this is trafﬁcked through Iran.14 In 2009, Iran bore the highest
fraction of the global opium (89%) and heroin (33%) seizures.15 The
number of injecting drug users in MENA is estimated to be
335 000–1 635 000, with a mean prevalence of 0.24%.16 Injected
drug use was the most common mode of HIV transmission among
men in Iran (73.5%) and Afghanistan (60.2%) in 2011.8 While Iran
has had the highest numbers among all countries in the region
(185 000, 0.43%), it is followed by Pakistan (117 000) and Egypt
(89 000), where injecting drug use contributed 20% and 23%,
respectively, of all newly notiﬁed cases in 2011; the lowest number
(1000; 0.03%) was reported in Somalia.15
HIV prevalence was assessed among PWID in nine countries in
the MENA region, with an estimated median of 8% (interquartile
range (IQR) 1–21%).13,15 However, there seems to be considerable
inter- and intra-country variability, ranging from 0% in Jordan,
Palestine, and some parts of Libya to 9.4–15.3% in Iran and as much
as 87% in Tripoli and other regions in Libya.15,17–19 Iran is the only
country with conclusive evidence for an established concentrated
epidemic at the national level.15 In addition to Iran, Pakistan, which
has also recorded high levels of HIV among PWID, has shown an
increasing trend over the years. In Pakistan, after almost two
decades of very low HIV prevalence among PWID, the prevalence
started to increase after 2003 and showed a consistent increase
across all rounds of IBBS from 10.8% in 2005 to 37.8% in 2011.20
Similarly, in Iran HIV prevalence among PWID increased from
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low (0–3.1%) among PWID in Jordan, Lebanon, Palestine, Syria, and
Tunisia.15
Emerging HIV epidemics have been seen among PWIDs in
Afghanistan, Egypt, Morocco, and Libya. In Egypt, where HIV
prevalence was very low for about two decades, it had increased to
6–7% in the IBBS run in 2010.21 In Afghanistan and Morocco, the
HIV epidemic among PWID appears to be emerging with
considerably high HIV prevalence in some settings, but still low
in others.22,23 Libya, with the highest reported prevalence, also has
a concentrated epidemic, but the trend is unclear.24 The reported
prevalence up to 21.1% in Bahrain and 27% in Oman suggests at
least some pockets of HIV infection among PWID.25,26
HIV incidence among PWID is also variable, ranging from 2.2/
100 person-years in Kabul, Afghanistan to 17.2/100 person-years
in Tehran, Iran.27,28
The key risk behavior among PWID is non-sterile equipment. In
the second round of IBBS in Iran, among those who had injected
drugs over the last month, 36.9% had used a non-sterile needle and
12.6% had practiced shared injection.18 Similarly, 39.2% of PWID
reported sharing a needle/syringe during their last injection in
Pakistan.20 The lifetime prevalence of sharing needles/syringes
ranges from 71% in Jordan to 97% in Oman. PWID inject drugs at a
median of 2.2 injections/day, ranging from 3.3 in Iran to 5.7 in
Afghanistan.15
The majority of PWID in MENA are sexually active and report high
levels of sexual risk behavior, with 29–60% reporting multiple
partners.16 In Iran, 30.4% of PWID were found to have sold sex for
money, drugs, goods, or a favor over the past 12 months.18 In the last
round of IBBS in Pakistan, 13.9% of PWID had paid a FSW for sex in the
past month, and 7.1% of PWID had had sex with either a male sex
worker or a Hijra sex worker. Hijra is a unique form of gender role
expression in South Asia and is an umbrella term used for individuals
who are transgender, trans-sexual, or bi-sexual, and identify as
female, although they are most often biologically male.20
Condom use among PWID is low to intermediate; 36% reported
ever using condoms.15 The rate of condom use was found to be
lowest in Afghanistan and Pakistan (10–38%) and highest in
Lebanon (88%).15 Eighteen percent of male PWID reported ever
having sex with men, and 45% reported having sex with a sex
worker.15
2.2. Men who have sex with men
In eight of 16 countries (50%) for which surveillance data were
available, the most commonly reported mode of transmission
among males was heterosexual sex, followed by ‘unknown mode’
in four countries.13 ‘Unknown mode of transmission’ was most
common in men in Oman (35.8%) and Saudi Arabia (60.9%) in 2011,
suggesting the possibility of male-to-male transmission, a factor
unlikely to be reported accurately due to the fear and reluctance to
disclose the true mode of transmission.13
In 2010, with the exception of Djibouti, Morocco, Somalia, and
Syria, the male-to-female ratio in reported HIV cases ranged from
1.4:1 in Oman to 7:1 in Bahrain, suggesting a considerable amount
of HIV transmission among MSM in some countries; on the other
hand, underreporting of female HIV cases may also account for this
ﬁnding.13 Male-to-male sex was reported as the most frequent
mode of HIV transmission only in Lebanon (50.0%) in 2011.13
The review of a limited number of reports revealed high inter-
and intra-country variability regarding HIV in MSM. Only one-
third of the countries – Tunisia, Sudan, Egypt, Morocco, Pakistan,
Yemen, and Lebanon – conducted IBBS in MSM. The prevalence
was found to vary between 3.6% in Lebanon in 2007 to 9.3% in
Sudan in 2005, and the highest measured prevalence was 13.0% in
Tunisia in 2011.13 While estimates of the size of vulnerablepopulations were obtained by primary data collection only in
Pakistan and Morocco, the remaining countries based their
estimates mainly on consensus of different stakeholders.13,20 In
the 2011 round of mapping in Pakistan, the size estimation was
1.9/1000 (male population) for Hijra sex workers and 1.6/1000 for
male sex workers.20 It is of note that no country has HIV prevalence
trend data in MSM.13
In a systematic review in Morocco, HIV prevalence among MSM
varied between 0 and 11%, with very limited data; 3.7% of men
(aged 15–24 years) reported ever having anal sex with a man, and
8.3% of truck drivers reported a same-sex sexual partner.23,29
In another study including MSM in two cities in Morocco –
Agadir and Marrakesh – more than 67% stated bisexual experi-
ences.30 The rate of selling sex among MSM was high (>65%). The
majority (78%) of the interviewees had practiced anal sex within
the past 6 months. The rate of condom use with commercial male
sex partners (59%) and regular male sex partners (44%) was low.
Approximately 81% had had sex with a woman at least once.
In Tripoli, Libya, HIV prevalence among MSM was much lower
(3.1%) compared to FSWs. The rate of having more than three anal
sex partners was high (44.2%). Only 21% used condoms consis-
tently. Among those who had anal sex with a commercial partner
(26.5%), 19.5% used a condom. A high number of MSM (53%) also
had sex with a female sex partner. The rate of ever injecting drugs
was low (4%) in this population.19
A report from Cairo, Egypt revealed that 65.8% of MSM were
engaged both in receptive and insertive anal sex, with 21.9% having
more than one sexual act per day. The number of partners per week
was high (3–4) among 35.6%. Approximately 38% also had
heterosexual relations. While 52.1% never used condoms, 21.9%
had never heard of condoms.31 The rate of ever using condoms was
as low as 23.9% in some regions in Lower Egypt.32
High HIV prevalence rates among MSM (7.8% among insertive
and 9.3% among receptive MSM) were reported from Sudan.33 The
rates of condom use among MSM showed signiﬁcant variation (8–
20%) in 2011 and 2012.34
2.3. Female sex workers
While there is a large body of evidence for concentrated
epidemics among PWID and considerable evidence for MSM in the
MENA region, evidence is lacking for FSWs.35
Eleven countries have conducted BBS or HIV sero-surveys in
FSWs, and the prevalence seems to be below 4% in all countries
except Somalia (5.2%, 2007), Iran, and Djibouti.13,36 The HIV
prevalence among FSWs in the IBBS including 14 cities in
Iran revealed an HIV prevalence of 4.5% in 2011,37 whereas
a respondent-driven sampling (RDS) survey in Shiraz found a
slightly higher rate of 5.2%.13 Although HIV prevalence trend data
are available in Morocco (2.6% in 2007; 2.7% in 2010) and Djibouti
(19.7% in 2007; 15.4% in 2009), these ﬁgures are the results of
facility-based surveillance in FSWs based on convenience sam-
ples.13
In Morocco, HIV prevalence among FSWs was around 2% and
had been stable for more than a decade.23 However, there seemed
to be considerable variation across regions, with prevalence rates
up to 8%. The rate of injected drug use among FSWs was found to be
low (3.7%), and consistent condom use during vaginal, anal, and
oral sex was 59.5%, 16.1%, and 16.9%, respectively.23
Tripoli, Libya had the highest reported HIV prevalence among
PWID; HIV prevalence was also quite high (15.7%) among FSWs, of
whom 18.2% had been forced to have sex. The number of sexual
partners during the last 6 months was between 10 and 50 in 42.8%
and >50 in 30.5%. Regular condom use with casual clients during
the last 6 months was reported by 63.4%. Injecting drug use was
low among FSWs (2/69).19
D. Go¨kengin et al. / International Journal of Infectious Diseases 44 (2016) 66–73 69A study from Greater Cairo showed that condom use during the
last month and with the last client was low (32.8% and 22.4%,
respectively) among FSWs. Around 5% of FSWs were injecting
drugs.38
In an IBBS including 14 sites in Sudan in 2011, HIV prevalence was
1% at 10 sites, with the highest HIV prevalence being 5.0% and 7.7%
at two sites. The age of starting to sell sex was <18 years in at least
one-ﬁfth of FSWs at 10 sites, with a signiﬁcantly high proportion
(47.8–50.1%) at two sites. The rate of condom use with the last client
(4.7–55.1%) and consistent condom use within the past month (0.7–
24.5%) varied signiﬁcantly. Testing for HIV was low; less than 10% of
FSWs had ever been tested for HIV at six sites.39
2.4. Mobile populations
Globally, mobile populations are at higher risk of acquiring HIV
due to poor living conditions and lack of access to medical care and
prevention. MENA is home to large numbers of migrants and
refugees who travel from North Africa to Europe and from Egypt,
Sudan, Jordan, and Yemen to the gulf countries (Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia, and UAE) where demand for foreign
labor is high. In Qatar and UAE, migrants make up more than 90% of
the total labor force. Recent conﬂicts in the region have expanded
the already large internally displaced and refugee population in the
MENA region. Most vulnerable are the victims of human trafﬁcking
(mostly women) whose numbers are rising in the MENA region,
especially in Sudan, Syria, and Yemen.40
2.5. Intimate partners of key populations
Evidence suggests that many members of the KPs described
above have intimate relationships with partners to whom they
may or may not have disclosed the extent of their risk.19,20,35,37,38
This also puts the intimate partners of these key, at-risk
populations at high risk of infection. In a study in Iran,17 HIV
prevalence among non-injecting female sexual partners of male
PWID was 2.8% (0.7–11.3%), which is twenty times the estimated
adult prevalence in Iran. However, direct measures of HIV
prevalence and related factors among the partners of KPs are rare
globally, and particularly in the MENA region.41
3. Other factors that contribute to the epidemic
3.1. Young people and HIV
The youth population aged 15–24 years in the MENA region
increased from 45 million in 1985 to around 90 million in 2010,
becoming the largest cohort in the history of the region.42 This
population is characterized by considerable diversity. While
overall prevalence rates for the young population are generally
low, young people who are members of KPs – like young PWID,
those who are sexually violated, who are in the sex trade, on the
street, young males who have sex with males, and young people
who are caught in armed conﬂict – are at especially high risk.43,44
The number of new HIV infections among young people aged 15–
24 years in the region was estimated to vary between
3000 and11 000.41
3.2. HIV testing
Outreach to sex workers, MSM, and PWID is critical, because
they are most at risk of acquiring HIV and they are thought to
contribute to a signiﬁcant proportion of new infections in the
region. However, reaching these populations is challenging,
because their behaviors are usually considered illicit and very
often illegal. For example, between 1989 and 2007, less than 5% ofHIV tests performed in this region included these populations and
more than 90% involved migrants screened for entry and residence
in the country.40 The low number of testing of pregnant women
also should be noted. Major challenges for access to testing are the
high levels of stigma and discrimination associated with testing for
HIV and conﬁdentiality issues, and the lack of HIV testing and
counseling ofﬁcers, especially those trained in caring for stigma-
tized populations across the region.45
3.3. Access to antiretroviral treatment
Recent reports indicate that antiretroviral treatment (ART)
reduces the HIV transmission risk,46 and as the ART coverage rate
increases, HIV incidence decreases; this is described as ‘treatment
as prevention’.47–49 The rate of ART coverage has increased
signiﬁcantly in the region within the last decade. However, by
the end of 2013, the ART coverage level in the region was still the
lowest throughout the world at 11%. While the efforts made so far
by all countries in the region have contributed to an increase in the
number of people receiving treatment, the rapidly growing
number of new HIV infections seems to be a major obstacle to
closing the gap. In 2013, less than one out of eight PLWH eligible for
ART received it in Djibouti, Iran, Egypt, Somalia, Sudan, and Yemen.
As a result, the region has experienced a signiﬁcant increase in
mortality from AIDS reaching 17% in 2012.50
3.4. Women and the prevention of mother-to-child transmission
Although the number of males infected with HIV in the MENA
region is greater than the number of infected females, the
increasing trend among women is remarkable. As an example,
the incidence of infection among women in Morocco and Yemen
between the years 2001 and 2012 increased signiﬁcantly, from an
estimated 4400 to 11 000 per year and from 1300 to 7700 per year,
respectively.50 About half of Morocco’s new HIV infections are
among women, nearly three-quarters of whom have acquired the
infection from their husbands.40 Similarly in Iran, three-quarters of
HIV-infected women had acquired the virus from their husbands,
who were mostly PWID.51 Women are particularly vulnerable to
HIV infection through their infected husbands. Cultural, economic,
and social factors combined with transactional sex, lack of
comprehensive sexual and reproductive health services, including
HIV testing, and very low access to treatment also seem to
contribute to the vulnerability of women.52
As the number of women living with HIV grows in the region, so
does mother-to-child transmission, in the absence of adequate
preventive measures. The highest recorded HIV prevalence among
pregnant women was in South Sudan (3.4% in 2007 decreasing
to 3.0% in 2009), followed by Djibouti (2.1% in 2007 to 1.6% in
2009).13
Although the governments of MENA countries have adopted the
global targets of reducing the number of new HIV infections among
children by 90% and the number of AIDS-related maternal deaths
by 50% between 2011 and 2015, in 2012 fewer than 10% of
pregnant women living with HIV in the MENA region received ART,
which is the lowest among world regions; by comparison, rates for
North America, Europe, and the Caribbean are above 95%.40
3.5. Stigma and discrimination
Stigma and discrimination of PLWH is a major factor in creating
a hidden population that is extremely difﬁcult to reach. Strong
moral views on HIV in many Muslim countries prevalent both in
the community and among healthcare workers create deeply
rooted stigma and discrimination against PLWH and those
perceived to be at high risk of infection.53 This prejudice is a
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treatment programs to seek support and care.11 In a study from
Egypt including 153 PLWH, nearly half (51.6%) of interviewed
individuals reported feeling stigmatized by others and 43.1%
reported changes in people’s views towards them. Nearly two
thirds of PLWH (66.7%) isolated themselves from their community
because of fear of stigma and 44.4% reported changes in the
behavior of their relatives. More than half (53.6%) of PLWH felt
useless to their community. Reported self-stigma was much
greater than stigma by others.54
Stigma in the healthcare setting is another major issue. Nursing
students in Saudi Arabia reported substantial negative attitudes
toward PLWH despite relatively high levels of knowledge about
AIDS.55 In another study from Iran, PLWH reported that healthcare
providers had a tendency to hold negative perceptions of drug
injection, sex work, and faithlessness. With no exception, all
participants had experienced denial of care and service by
healthcare providers.56 Fear of stigma also has negative effects
on access and adherence to ART.57
4. Successes and challenges
Despite all of the unfavorable conditions, there have been many
improvements in the response of MENA countries to HIV, although
at a very slow pace. Some countries (Egypt, Iran, and Morocco, for
example) have made considerable progress, both in terms of
identifying the key characteristics of their epidemics and
responding accordingly.41
As indicated above, four countries – Pakistan, Egypt, Lebanon,
and Tunisia – have provided HIV prevalence estimates for FSW,
PWID, and MSM with four rounds of surveys available in
Pakistan.13,20,58 Eleven countries have conducted IBBS or HIV
sero-surveys in FSWs.13
Egypt identiﬁed the key characteristics of the epidemic with
BBSS run in 2006 and 2010.12,59 Voluntary counseling and
testing (VCT) centers – seven mobile and ﬁve ﬁxed – were
launched in 2005 in Egypt,60 and harm reduction interventions
targeting PWID were established in 2008, including peer
education on safe sex and safe injection, HIV voluntary
counseling and testing using rapid test kits, medical services
for the management of sexually transmitted infections, and the
distribution of behavior-change communication booklets and
brochures, needles, and condoms free of charge.59 In Morocco,
VCT uptake increased signiﬁcantly between 2010 and 2013.61
Morocco ran several testing campaigns to scale-up HIV testing
throughout the country.62,63
Although there have been serious efforts to increase ART
coverage, only two countries – Djibouti and Morocco – provided
treatment to 20–40% of adults and children living with HIV.
Morocco increased the number receiving ART 20-fold within <10
years; Djibouti enhanced coverage from 19% in 2010 to 36% in
2012.6 The number of PLWH receiving ART reached 3400 in Algeria
by 2012 compared to 2900 in 2011, and the new target is 80% by
2015.40 In the remaining countries in the region, fewer than 20% of
PLWH had access to treatment.6
Harm reduction programs are implemented in many MENA
countries to varying degrees, with needle and syringe exchange
programs in Jordan, Egypt, Syria, Lebanon, Morocco, and Tunisia.
Bahrain, Iran, Lebanon, Morocco, and UAE provide opioid
substitution therapy.61,64
Only two countries in the region managed to reduce their rates
of new infections in 2013 from 2005 levels – The Islamic Republic
of Iran (4% reduction) and Djibouti.6 Similarly, only two countries –
Djibouti (by 70%) and Somalia (by 22%) – have reduced the number
of new HIV infections among newborns and children in the period
2005–2013.6The ﬁrst HIV outbreaks among PWID in Iran were reported
around 1996. HIV prevalence then increased considerably in the
early 2000s, reaching a peak by 2005. Despite some socio-cultural
barriers, the implementation of successful harm reduction
programs and opioid replacement therapy decreased the preva-
lence by 16% in 2006 and the stabilization continued in the
following years.65,66 HIV prevalence in the 2006 and 2010 multi-
city IBBS was stable at 15%;18 sexual transmission of HIV remained
relatively stable until 2006, standing at 5–6%, yet has been rising
continuously, reaching 20.7% in 2010.66 The biannual surveillance
of PWID, FSWs, partners of PWID, and prisoners since 2009 has
provided insights into the epidemic, and effective measures taken
over the past 10 years have successfully slowed the progression of
the epidemic among PWID; however, Iran has failed to address the
needs of MSM, partners of PWID, and clients of FSWs.67
In the past 4 years, Oman has established a strong program to
eliminate HIV transmission from mothers to their children,
offering HIV testing to all pregnant women with an acceptance
rate of 99% and with almost universal antenatal care. Algeria, Iran,
Morocco, and Tunisia have similar interventions.6,40 In Tunisia,
almost 80% of pregnant women living with HIV receive ART.40 A
pilot program for the prevention of mother-to-child transmission
(PMTCT) has been implemented in three regions in Morocco. A plan
to eliminate mother-to-child transmission has been developed for
the period 2012–2016. This includes efforts to engage private
health providers in providing HIV testing and awareness for
pregnant women, and one-third of pregnant HIV-positive women
receive ART.40,68
Access to services for preventing mother-to-child transmission
in Somalia started in late 2010, and 35 health facilities were
providing PMTCT at the end of 2012. The rate of HIV testing in
2012 ranged between 23% and 43%, according to the region.
Revitalizing PMTCT in Somalia has been a signiﬁcant achievement.
However, the rate is 3% in terms of coverage, with an estimated
unmet need of more than 95%.69,70
The Arab Strategic Framework for the Response to HIV and AIDS
(2014–2020) endorsed by the Council of Arab Ministers of Health,
aims to support Arab States to achieve the goals and targets of the
2011 United Nations General Assembly High Level Meeting on HIV
and AIDS.71 The Arab AIDS Strategy includes 10 goals. It promotes
engagement and emerging leadership from countries, and men-
tions addressing issues including HIV-related restrictions on entry,
stay and residence and KPs for HIV, as well as HIV in conﬂict and
post-conﬂict settings,6 yet leaves the deﬁnition of KPs to each
government to decide.
5. The role of civil society
Civil society’s deep involvement in the HIV response has been
seen globally since the early days of the HIV epidemic.72 This
association has become evident in the MENA region in the last
decade, with civil society organizations (CSOs) becoming front
liners in working for advocacy and prevention, and other efforts
being made in lobbying around issues of funding and treatment.
Yet perhaps the most important role of civil society in the MENA
region has been how it has managed to maintain close contact with
members of KPs throughout their different programs of service
provision,73,74 outreach, and prevention.75 This cannot be gener-
alized over the whole region, since a more hostile environment
persists in most countries, but progress can clearly be seen in
countries like Morocco, Tunisia, Algeria, and Lebanon, where civil
society is a main player – in collaboration with national AIDS
programs – in the HIV response.
In the past few years, the rise of multiple regional platforms and
networks has been evident in the region, such as the Regional/Arab
Network Against AIDS (RANAA),76 the Middle East and North Africa
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drugs, and ITPC MENA for treatment and prevention, alongside
other networks targeting speciﬁc KPs such as MENARosa for
women living with HIV, the Middle East and North Africa Network
for People who use Drugs (MENAnpud),77 and M-Coalition78 for
MSM. These networks highlight the successful experiences at the
national regional level as a learning opportunity for partnerships
and collaborations, but also as a method of lobbying key policy
makers. The engagement of civil society by governments has been
a turning point in the HIV response, and now donors such as the
Global Fund require this for ﬁnancial support, with a full
understanding of the important role that community members
and their representatives can play in shaping the next phase of the
epidemic.
6. Conclusions and the path forward
In the last few years, many countries in the region have been
affected by social and political unrest and conﬂict, which may be
attributed to longstanding dictatorships, human rights violations,
political corruption, economic decline, unemployment, and
extreme poverty throughout the region. Cumulatively, these have
potential serious implications for the region’s HIV epidemic, such
as disruption in the implementation of prevention and advocacy
programs, interference with service delivery, and high levels of
mobility and displacement. The latter may cause or be a result of
crowding, unhealthy living conditions, high levels of violence, sex
work, and alcohol and substance abuse.1,2 Combining the above
with the very young demographic and high unemployment in the
region42 could make the current epidemic very volatile and
something that needs to be given a high priority by the
international agencies.
It is clear that there is an emerging HIV epidemic in the MENA
region. Although the number of PLWH is the lowest globally since
the emergence of the virus, the HIV burden is increasing rapidly,
with rising numbers of AIDS-related deaths.
Despite unfavorable conditions, many countries in the region
have put signiﬁcant effort into the scale-up of their response to this
growing epidemic, such as developing national strategies and the
implementation of programs for KPs, indicating an increased
political will in the region to address the HIV epidemic. Those
countries that have learned from the experiences of others that
have faced a more devastating epidemic and have translated this
into a robust response to HIV have made signiﬁcant progress. On
the other hand, the response to HIV in other countries has been
slower due to denial, stigma, and a reluctance to address sensitive
issues.
The time for algorithms and establishing models of the
epidemic in the region is done. Creating and implementing
speciﬁc, culturally suitable programs that could address the
denial and stigma in the region appropriately is the key to a
timely and appropriate response. We need to highlight and
document best practices in speciﬁc countries in the region
and be able to translate these to other countries. In addition,
IBBS of KPs, along with size estimations, should be the main
approach of surveillance efforts in all countries, followed by the
development and implementation of programs addressing the
speciﬁc needs of the populations surveyed. Moreover, de-
stigmatization of populations most at risk of HIV on a human
rights basis is essential for outreach for surveillance and
prevention. For this, we need to use all of our national and
international resources; the HIV epidemic in the MENA region is
still at a controllable level, and this opportunity should not be
missed.
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